Pitcairn Co. increased its stake in shares of Illumina Inc. (NASDAQ:ILMN) by 33.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,656 shares of the life sciences company’s stock after buying an additional 1,157 shares during the period. Pitcairn Co.’s holdings in Illumina were worth $654,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the stock. Physicians Financial Services Inc. boosted its stake in shares of Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock valued at $103,000 after buying an additional 700 shares in the last quarter. Checchi Capital Advisers LLC boosted its stake in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock valued at $134,000 after buying an additional 22 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Illumina by 215.6% in the first quarter. IFP Advisors Inc now owns 1,133 shares of the life sciences company’s stock valued at $184,000 after buying an additional 774 shares in the last quarter. Simonbaker & Partners LLC bought a new stake in shares of Illumina during the first quarter valued at about $243,000. Finally, First Manhattan Co. boosted its stake in shares of Illumina by 90,000.0% in the second quarter. First Manhattan Co. now owns 1,802 shares of the life sciences company’s stock valued at $252,000 after buying an additional 1,800 shares in the last quarter. 95.22% of the stock is owned by institutional investors.

Illumina Inc. (NASDAQ:ILMN) traded up 0.50% during mid-day trading on Thursday, reaching $179.34. 1,098,852 shares of the company traded hands. The firm has a market cap of $26.29 billion, a PE ratio of 61.42 and a beta of 0.73. The stock’s 50-day moving average price is $170.44 and its 200-day moving average price is $154.09. Illumina Inc. has a one year low of $127.10 and a one year high of $196.47.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The firm earned $600 million during the quarter, compared to the consensus estimate of $31.91 million. During the same period last year, the firm posted $0.80 EPS. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. Analysts forecast that Illumina Inc. will post $3.53 earnings per share for the current fiscal year.

ILMN has been the subject of several research reports. Vetr cut shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $167.08 price objective for the company. in a research note on Monday, July 18th. CL King started coverage on shares of Illumina in a research note on Tuesday, June 21st. They set a “buy” rating and a $165.00 price objective for the company. Argus upped their price target on shares of Illumina from $175.00 to $185.00 and gave the stock a “buy” rating in a research report on Monday, August 8th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $190.00 price target for the company in a research report on Friday, August 26th. Finally, Citigroup Inc. upped their price target on shares of Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, September 12th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $163.07.

In related news, EVP Christian O. Henry sold 716 shares of Illumina stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $141.89, for a total transaction of $101,593.24. Following the completion of the transaction, the executive vice president now directly owns 18,976 shares of the company’s stock, valued at approximately $2,692,504.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director A Blaine Bowman sold 5,000 shares of Illumina stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $147.14, for a total transaction of $735,700.00. Following the transaction, the director now directly owns 20,704 shares of the company’s stock, valued at $3,046,386.56. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina Inc. (NASDAQ:ILMN).

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.